Edition:
United States

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

22.71USD
20 Aug 2018
Change (% chg)

-- (--)
Prev Close
$22.71
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
133,228
52-wk High
$41.24
52-wk Low
$20.25

Select another date:

Thu, May 10 2018

BRIEF-La Jolla Pharmaceutical Co Announces $125 Mln Royalty Financing Agreement With Healthcare Royalty Partners

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES $125 MILLION ROYALTY FINANCING AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS Source text for Eikon: Further company coverage:

BRIEF-La Jolla Pharmaceutical Quarterly Loss Per Share $2.22

* LA JOLLA PHARMACEUTICAL ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2018 AND RECENT CORPORATE PROGRESS

BRIEF-La Jolla PharmaAnnounces Launch Of Giapreza In United States

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES LAUNCH OF GIAPREZA™ (ANGIOTENSIN II) IN THE UNITED STATES

BRIEF-La Jolla Pharmaceutical Announces Pricing Of Public Offering Of Common Stock

* SAYS PUBLIC OFFERING OF 3.40 MILLION COMMON SHARES PRICED AT $29.50PER SHARE

BRIEF-La Jolla Pharmaceutical Company Announces $100 Million Public Offering Of Common Stock

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES $100 MILLION PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-La Jolla Pharmaceutical Q4 Loss Per Share $1.74

* MPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS

BRIEF-La Jolla Pharmaceutical Announces Treatment Of First Patient In Giapreza Pediatric Study

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES THE TREATMENT OF FIRST PATIENT IN GIAPREZA (ANGIOTENSIN II) PEDIATRIC STUDY Source text for Eikon: Further company coverage:

Select another date: